Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on August 28, 2006

Circulation. 2006
Published online before print August 28, 2006, doi: 10.1161/CIRCULATIONAHA.106.630905
A more recent version of this article appeared on September 19, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
114/12/1234    most recent
CIRCULATIONAHA.106.630905v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Haan, S.
Right arrow Articles by Schotten, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Haan, S.
Right arrow Articles by Schotten, U.
Related Collections
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow Arrhythmias, clinical electrophysiology, drugs

Submitted on April 3, 2006
Revised on July 18, 2006
Accepted on July 21, 2006

AVE0118, Blocker of the Transient Outward Current (Ito) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat

Sunniva de Haan MD, Maura Greiser MD, Erik Harks PhD, Yuri Blaauw MD, PhD, Arne van Hunnik BSc, Sander Verheule PhD, Maurits Allessie MD, PhD, and Ulrich Schotten MD, PhD*

From the Department of Physiology, University Maastricht, Maastricht, the Netherlands.

* To whom correspondence should be addressed. E-mail: Schotten{at}fys.unimaas.nl.

Background--The loss of atrial contractile function after cardioversion of atrial fibrillation (AF) contributes to the thromboembolic risk associated with AF. The newly developed blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur) AVE0118 prolongs atrial action potential duration and might therefore enhance atrial contractility. We compared the ability of AVE0118 to restore atrial contraction after cardioversion of AF with the efficacy of conventional positive inotropic compounds in the goat model of AF.

Methods and Results--Eighteen goats were chronically instrumented with epicardial electrodes, a pressure transducer in the right atrium, and piezoelectric crystals to measure right atrial diameter. Atrial contractility and refractoriness and QT duration were measured before and after 1 week (3 to 8 days) of AF induced by repetitive burst pacing. The measurements were repeated after administration of digoxin (0.02 mg/kg), dobutamine (5 µg · kg-1 · min-1), the Ca2+ sensitizer EMD57033 (1 mg · kg-1 · min-1), the L-type Ca2+ channel agonist BayY5959 (0.1 mg · kg-1 · min-1), and AVE0118 (0.01 to 0.2 mg · kg-1 · min-1). The effect of AVE0118 on the configuration of atrial monophasic action potentials was determined for comparison. After 1 week of AF, atrial contractility during sinus rhythm or slow atrial pacing was reduced to <10%. Digoxin and dobutamine failed to increase atrial contractility. EMD57033 restored 41% and BayY5959 restored 48% of atrial contractility at baseline. BayY5959 significantly prolonged QT duration by 24.7%. AVE0118 enhanced atrial contraction to 156% of the baseline value. The positive inotropic effect was accompanied by a pronounced prolongation of atrial action potential duration and refractoriness, whereas QT duration remained unchanged.

Conclusions--Conventional positive inotropic drugs showed limited effect on atrial contractility after cardioversion of AF or produced QT prolongation. In contrast, the Ito/IKur blocker AVE0118 fully restored atrial contraction without proarrhythmic effects on the ventricle.


Key words: electrophysiology • fibrillation • inotropic agents • ion channels • stroke




This article has been cited by other articles:


Home page
EuropaceHome page
I. Savelieva and J. Camm
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
Europace, June 1, 2008; 10(6): 647 - 665.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G.-R. Li, H.-B. Wang, G.-W. Qin, M.-W. Jin, Q. Tang, H.-Y. Sun, X.-L. Du, X.-L. Deng, X.-H. Zhang, J.-B. Chen, et al.
Acacetin, a Natural Flavone, Selectively Inhibits Human Atrial Repolarization Potassium Currents and Prevents Atrial Fibrillation in Dogs
Circulation, May 13, 2008; 117(19): 2449 - 2457.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
U. Schotten, S. de Haan, S. Verheule, E. G.A. Harks, D. Frechen, E. Bodewig, M. Greiser, R. Ram, J. Maessen, M. Kelm, et al.
Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange
Cardiovasc Res, January 1, 2007; 73(1): 37 - 47.
[Abstract] [Full Text] [PDF]